Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 12/20 | 0.63 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 4/20 | 0.49 |
| ▸ | DRD3 | P35462 | 4/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7759234 | 1.00 | OPRL1 (0.63) | OPRL1DRD2DRD4DRD3OPRM1 | |
| SCHEMBL7757070 | 0.89 | OPRL1 (0.68) | OPRL1DRD2DRD4DRD3OPRM1 | |
| SCHEMBL5098400 | 0.87 | OPRL1 (0.65) | OPRL1DRD2DRD4DRD3OPRM1 | |
| SCHEMBL5102059 | 0.87 | OPRL1 (0.65) | OPRL1DRD2DRD4DRD3OPRM1 | |
| SCHEMBL5102055 | 0.87 | OPRL1 (0.65) | OPRL1DRD2DRD4DRD3OPRM1 | |
| SCHEMBL5095004 | 0.87 | OPRL1 (0.70) | OPRL1DRD2DRD4DRD3OPRM1 | |
| SCHEMBL7995855 | 0.85 | OPRL1 (0.65) | OPRL1DRD2DRD4DRD3OPRM1 | |
| SCHEMBL5805489 | 0.84 | OPRL1 (0.63) | OPRL1DRD2DRD4DRD3OPRM1 | |
| SCHEMBL7999901 | 0.84 | OPRL1 (0.62) | OPRL1DRD2DRD4DRD3OPRM1 | |
| SCHEMBL7760247 | 0.84 | OPRL1 (0.62) | OPRL1DRD2DRD4DRD3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287478-A1 | Nociceptin Analogues and Uses Thereof | ZEALAND PHARMA A/S (DK) | 2008-11-20 | — | — | US | disclosed |
| US-6277991-B1 | FOR TREATMENT OF MIGRAINE, NON-INSULIN DEPENDENT DIABETES MELLITUS, SEPSIS, INFLAMMATION, INCONTINENCE, VASOMOTOR DISTURBANCES SUCH AS HOT FLUSHES OR HOT FLASHES | NOVO NORDISK A/S (DK) | 2001-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287478-A1 | Nociceptin Analogues and Uses Thereof | OPRL1, NPSR1, OPRK1 | OPRL1 1/4885DRD2 753/4885DRD4 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.